The FDA has withdrawn emergency use authorization for the drugs chloroquine and hydroxychloroquine, saying they're likely not effective in treating COVID-19.
Hydroxychloroquine and chloroquine were initially designed as anti-malarial drugs and later shown to be useful in treating certain autoimmune disorders.
Early on in the pandemic, some researchers thought the drugs might be useful in treating COVID-19. Laboratory tests showed hydroxychloroquine interfered with the ability of the coronavirus that causes COVID-19 to enter cells. There were also hints from the use of the drugs in patients that they might be helpful. The FDA
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA terminates emergency use authorization of hydroxychloroquine for Covid-19The FDA pulls its emergency use authorization of hydroxychloroquine for Covid-19 treatment, citing the latest scientific evidence
続きを読む »
FDA Pulls Emergency Covid-19-Use Approval for Two Malaria Drugs Touted by TrumpBreaking: The FDA has revoked its emergency-use authorization for two malaria drugs, chloroquine and hydroxychloroquine, for the treatment of Covid-19. Both were widely touted by President Trump and others as useful in helping coronavirus patients.
続きを読む »
FDA pulls emergency use authorization of hydroxychloroquine for COVID-19BREAKING: FDA rescinds emergency use authorization for hydroxychloroquine to treat hospitalized COVID-19 patients, saying the drug carries too many risks without any apparent benefit.
続きを読む »